This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Baricitinib for moderate to severe atopic dermatitis

< Back

Baricitinib for moderate to severe atopic dermatitis


Skin Disease, Burns and Wound Care

March 2019

Baricitinib is in development for the treatment of adults with moderate to severe atopic dermatitis (AD) which is also known as eczema or atopic eczema. AD is a chronic inflammatory skin disease that affects both children and adults and is characterized by redness, itchiness, and scaling of the skin. Some people only have small patches of dry skin, but others may experience widespread red, inflamed skin all over the body. Patients with moderate to severe AD could come across with sleep disturbances, anxiety, depression, and poor quality of life. Currently, the management of AD involves the removal or treatment of trigger factors that contribute to the development of the disease.
Baricitinib acts by selectively and reversibly blocking the janus-associated kinase (JAK) enzymes that mediate the pathways involved in the inflammatory process in AD and other inflammatory diseases. Baricitinib is taken orally and is currently licensed for the treatment of moderate to severe active rheumatoid arthritis in adult patients that have not responded well to other therapies. If licensed, baricitinib will offer an additional treatment option for adults with moderate to severe AD.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Version


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts